Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
5 "Morbidity"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Genitourinary cancer
Cause of Mortality after Radical Prostatectomy and the Impact of Comorbidity in Men with Prostate Cancer: A Multi-institutional Study in Korea
Sahyun Pak, Dalsan You, In Gab Jeong, Dong-Eun Lee, Sung Han Kim, Jae Young Joung, Kang-Hyun Lee, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn
Cancer Res Treat. 2020;52(4):1242-1250.   Published online July 3, 2020
DOI: https://doi.org/10.4143/crt.2020.286
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to examine the causes of death in Korean patients who underwent radical prostatectomy for prostate cancer and investigate the relationship between comorbidity and mortality.
Materials and Methods
We conducted a retrospective multicenter cohort study including 4,064 consecutive patients who had prostate cancer and underwent radical prostatectomy between January 1998 and June 2013. The primary endpoint of this study was all-cause mortality, and the secondary endpoints were cancer-specific mortality (CSM) and other-cause mortality (OCM). Charlson comorbidity index (CCI) was calculated to assess the comorbidities of each patient.
Results
Of 4,064 patients, 446 (11.0%) died during follow-up. The cause of death was prostate cancer in 132 patients (29.6%), other cancers in 121 patients (27.1%), and vascular disease in 57 patients (12.8%) in our cohort. The overall 10-year CSM rate was lower than the OCM rate (4.6% vs. 10.5%). The 10-year CSM rate was lower than the OCM rate in low- to intermediate-risk group patients (1.2% vs. 10.6%), whereas they were similar in high-risk group patients (11.8% vs. 10.1%). In the multivariable analysis, CCI was independently associated with all-cause mortality after radical prostatectomy, regardless of age and pathologic features.
Conclusion
Death from prostate cancer was rare in Korean men who underwent radical prostatectomy. Clinicians should be aware of the possibility of overtreatment of low-risk prostate cancer in men with significant comorbidity. Our findings may help to facilitate counseling and plan management in this patient group.
  • 7,089 View
  • 111 Download
  • 3 Web of Science
Close layer
Risk of Second Primary Cancer in People with Non-melanoma Skin Cancer: A Nationwide Cohort Study
Shu-Hui Wang, Ching-Chi Chi, Zi-Hao Zhao, Tao-Hsin Tung
Cancer Res Treat. 2018;50(2):428-435.   Published online May 10, 2017
DOI: https://doi.org/10.4143/crt.2017.110
AbstractAbstract PDFPubReaderePub
Purpose
Previous western studies have found Caucasians with skin cancer, either melanoma or nonmelanoma skin cancer (NMSC), have an elevated risk of second primary cancer. Our objective was to assess the risk of second primary cancer in Taiwanese with NMSC.
Materials and Methods
By using data from Taiwan’s National Health Insurance Research Database, we conducted a population-based cohort study to assess the risk of incident second primary cancer in Taiwanese affected by NMSC.
Results
We identified 505 subjects with NMSC and 2,020 matched controls. After adjustment for potential confounders including age, sex, urbanization, and Charlson Comorbidity Index, people who had NMSC had a 1.43-fold (95% confidence interval [CI], 1.05 to 1.96) risk for the development of second primary cancer as comparedwith control group. Menwith NMSC had a 2.99-fold (95% CI, 1.00 to 9.10) risk for second primary cancer involving the lip, oral cavity, and pharynx and a 3.51-fold (95% CI, 1.21 to 10.17) risk for second primary cancer involving the genitourinary organs when compared to the control group. By contrast, women with NMSC did not have an increased risk of second primary cancer.
Conclusion
This study revealed Asians with NMSC have an increased risk of second primary cancer. Our findings can be a useful reference for health care for people diagnosed with NMSC.

Citations

Citations to this article as recorded by  
  • Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review
    Ashmitha Kumar, Arunan Jeyakumar, Alfred K. Lam, Vinod Gopalan
    Leukemia Research.2024; 147: 107610.     CrossRef
  • Non‐melanoma skin cancer as a clinical marker for internal malignancies: a nationwide population‐based cohort study
    S.J. Yun, J.M. Bae, H. Kim, B.C. Park, J.S. Kim, S.H. Seo, H.H. Ahn, D.Y. Lee, Y.C. Kim, H.J. Park, K.Y. Chung
    Journal of the European Academy of Dermatology and Venereology.2020; 34(4): 746.     CrossRef
  • 10,586 View
  • 170 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Clinicopathologic Characteristics and Prognosis of Tongue Squamous Cell Carcinoma in Patients with and without a History of Radiation for Nasopharyngeal Carcinoma: A Matched Case-Control Study
Peng Zhang, Li Zhang, Hui Liu, Lei Zhao, Yong Li, Jing-Xian Shen, Qing Liu, Meng-Zhong Liu, Mian Xi
Cancer Res Treat. 2017;49(3):695-705.   Published online October 11, 2016
DOI: https://doi.org/10.4143/crt.2016.317
AbstractAbstract PDFPubReaderePub
Purpose
Previous studies reported an association between an increased risk of tongue cancer and radiation treatment for nasopharyngeal carcinoma (NPC). This study compared the clinicopathologic characteristics and outcomes of tongue squamous cell carcinoma (TSCC) in patients with and without a history of radiotherapy for NPC.
Materials and Methods
From 1965 to 2009, a total of 73 patients were diagnosed with TSCC with a history of radiotherapy for NPC. The patients were matched in a 1:3 ratio with patients with sporadic TSCC according to age, sex, and year of the TSCC diagnosis. The primary endpoint was the overall survival.
Results
The median interval from NPC to TSCC was 82 months. The NPC survivors were more likely to be diagnosed with a more advanced T classification, less likely to have lymph node involvement, and more likely to have the tumor located in the dorsum of the tongue than sporadic TSCC. Regarding the histologic characteristics, the NPC survivors were more likely to have a weak lymphocytic host response, low tumor budding, and low risk of a worse pattern of invasion. The sporadic TSCC patients had a better overall survival (hazard ratio, 0.690; p=0.033) than the NPC survivors. In competing risks analysis, the cumulative incidence functions for the competing event (documented non-tongue cancer death) were significantly higher in the NPC survivors (Gray’s test, p=0.001).
Conclusion
TSCC patients with a history of radiotherapy for NPC appear to have particular clinicopathologic features, a poorer survival, and are more likely to die from non-tongue cancer causes than those with sporadic TSCC.

Citations

Citations to this article as recorded by  
  • Radiotherapy upregulated immune checkpoints contribute to the development of second primary OSCC
    Li Wang, Siyu Wang, Jiayu Zhang, Jianmin Peng, Bin Cheng, Huan Li, Qinchao Hu
    Oral Diseases.2024; 30(4): 2188.     CrossRef
  • Impact of histopathological parameters in prognosis of oral squamous cell carcinoma
    R. P. Ekanayaka, W. M. Tilakaratne
    Oral Diseases.2024;[Epub]     CrossRef
  • Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma
    James C. H. Chow, Wah Cheuk, William C. S. Cho, Chi-Fai Wong, Dennis W. Y. Au, Anthony H. P. Tam, Rachel C. W. Wong, Jeffrey C. H. Chan, Simon C. C. Law, Roger K. C. Ngan, Kam-Hung Wong, Ka-Man Cheung
    JAMA Network Open.2023; 6(7): e2323890.     CrossRef
  • Clinical characterization of radiation-associated muscle-invasive bladder cancer
    Sybil T. Sha, Edward Christopher Dee, Matthew Mossanen, Brandon A. Mahal, Cierra Zaslowe-Dude, Trevor J. Royce, Michelle S. Hirsch, Guru Sonpavde, Mark A. Preston, Paul L. Nguyen, Kent W. Mouw, Vinayak Muralidhar
    Urology.2021; 154: 208.     CrossRef
  • SPP1 and FN1 are significant gene biomarkers of tongue squamous cell carcinoma
    Xiao-Liang Xu, Hui Liu, Ying Zhang, Su-Xin Zhang, Zhong Chen, Yang Bao, Tian-Ke Li
    Oncology Letters.2021;[Epub]     CrossRef
  • Secondary Squamous Cell Carcinoma of the Oral Cavity after Nasopharyngeal Carcinoma
    Liyuan Dai, Qigen Fang, Peng Li, Junfu Wu, Xu Zhang
    Cancer Research and Treatment.2020; 52(1): 109.     CrossRef
  • Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG
    James C.H. Chow, Anthony H.P. Tam, Ka-Man Cheung, Victor H.F. Lee, Chi-Leung Chiang, Macy Tong, Edwin C.Y. Wong, Alice K.W. Cheung, Sunny P.C. Chan, Jessica W.Y. Lai, Roger K.C. Ngan, Wai-Tong Ng, Anne W.M. Lee, Kwok-Hung Au
    Oral Oncology.2020; 111: 105012.     CrossRef
  • BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma
    Miao Wang, Lu Zhao, Dongdong Tong, Linrui Yang, Hongjie Zhu, Qing Li, Fenghe Zhang
    International Immunopharmacology.2019; 76: 105921.     CrossRef
  • Surgical treatment of early tongue squamous cell carcinoma and patient survival
    Lansheng Zhu, Yanling Wang, Rui Li, Aiqun Liu, Xiaoping Zhang, Chunran Zuo, Xiaoting Xu
    Oncology Letters.2019;[Epub]     CrossRef
  • Keratin 6A gene silencing suppresses cell invasion and metastasis of nasopharyngeal carcinoma via the β‑catenin cascade
    Chuanjun Chen, Huiguo Shan
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Tumour budding in oral squamous cell carcinoma: a meta-analysis
    Alhadi Almangush, Matti Pirinen, Ilkka Heikkinen, Antti A Mäkitie, Tuula Salo, Ilmo Leivo
    British Journal of Cancer.2018; 118(4): 577.     CrossRef
  • The poor outcome of second primary oral squamous cell carcinoma is attributed to Bmi1 upregulation
    Qinchao Hu, Tong Wu, Xiaobing Chen, Huan Li, Zhicheng Du, Yuantao Hao, Jianmin Peng, Shanshan Tai, Ming Song, Bin Cheng
    Cancer Medicine.2018; 7(4): 1056.     CrossRef
  • Clinical analysis of second primary gingival squamous cell carcinoma after radiotherapy
    Xiaoyan Fu, Shuwei Chen, Weichao Chen, Zhongyuan Yang, Ming Song, Hao Li, Huayong Zhang, Fan Yao, Xuan Su, Tianrun Liu, An-Kui Yang
    Oral Oncology.2018; 84: 20.     CrossRef
  • 11,335 View
  • 209 Download
  • 17 Web of Science
  • 13 Crossref
Close layer
Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients
Joo Ho Lee, Hong-Gyun Wu, Hak Jae Kim, Dong-Wan Kim, Se-Hoon Lee, Tae Min Kim, Young Whan Kim, Dae Seog Heo
Cancer Res Treat. 2012;44(4):242-250.   Published online December 31, 2012
DOI: https://doi.org/10.4143/crt.2012.44.4.242
AbstractAbstract PDFPubReaderePub
PURPOSE
The current study was conducted in order to evaluate the clinical outcome of radical radiotherapy (RT) with or without chemotherapy for elderly patients with stage III non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS
Between 1990 and 2010, 125 patients, aged 70 years or more, received radical RT with or without chemotherapy for treatment of stage III NSCLC. We reviewed the patients' prognostic factors, including comorbidities. Comorbidity status was evaluated using a simplified comorbidity score (SCS). Of the patients reviewed, 82 received radical RT alone, whereas the other 43 patients underwent chemoradiotherapy (CRT). A platinum-based chemotherapy regimen was most commonly used (42/43).
RESULTS
The two-year overall-survival (OS) and progression-free survival (PFS) rates were 32.2% and 21.8%, respectively. SCS was the independent prognostic factor for OS. In the frail elderly subgroup with a SCS of > or =10, CRT demonstrated a significant difference in PFS, but not in OS. In contrast, OS and PFS following CRT were significantly superior to RT in the fit elderly subgroup with a SCS of <10. The incidence of severe pulmonary toxicities in the frail elderly subgroup was significantly higher than that in the fit elderly subgroup.
CONCLUSION
Multiple comorbidities evaluated according to the SCS are related to poor OS in elderly patients with stage III NSCLC. CRT improved clinical outcome when compared to RT in the fit elderly subgroup, however, the gain from this treatment was negated in the frail elderly subgroup with multiple comorbidities. Therefore, evaluation of comorbidity is necessary in order to determine whether chemotherapy should be combined with RT in elderly patients with stage III NSCLC.

Citations

Citations to this article as recorded by  
  • Clinicopathological characteristics and prognosis of non-small cell lung cancer in Algeria: a single-center retrospective study
    Mohamed Lahmadi, Leila Beddar, Souad Ketit, Tarek Makhbouche, Narriman Laouar, Taha Filali
    BMC Cancer.2024;[Epub]     CrossRef
  • Considerations of Medical Preparedness to Assess and Treat Various Populations During a Radiation Public Health Emergency
    Thomas A. Winters, David R. Cassatt, Jenna R. Harrison-Peters, Brynn A. Hollingsworth, Carmen I. Rios, Merriline M. Satyamitra, Lanyn P. Taliaferro, Andrea L. DiCarlo
    Radiation Research.2023;[Epub]     CrossRef
  • Independent Predictors for Hospitalization-Associated Radiation therapy Interruptions
    Adam Hubler, Daniel V. Wakefield, Lydia Makepeace, Matt Carnell, Ankur M. Sharma, Bo Jiang, Austin P. Dove, Wesley B. Garner, Drucilla Edmonston, John G. Little, Esra Ozdenerol, Ryan B. Hanson, Michelle Y. Martin, Arash Shaban-Nejad, Maria Pisu, David L.
    Advances in Radiation Oncology.2022; 7(6): 101041.     CrossRef
  • Behandlung des Analkarzinoms
    Natalie Schindler, Irenäus A. Adamietz
    Der Onkologe.2021; 27(6): 615.     CrossRef
  • Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
    Magdalena Zaborowska-Szmit, Marta Olszyna-Serementa, Dariusz M. Kowalski, Sebastian Szmit, Maciej Krzakowski
    Cancers.2021; 13(18): 4534.     CrossRef
  • Cancer incidence and survival analysis among elderly people in Bingol province
    Burak METE, Vedat SÖYİLER, Bilal BUZGAN
    Cukurova Medical Journal.2020; 45(1): 290.     CrossRef
  • Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer
    Navneet Singh, Potsangbam Sarat Singh, Ashutosh N. Aggarwal, Digambar Behera
    Clinical Lung Cancer.2016; 17(3): 205.     CrossRef
  • A review of the management of elderly patients with non-small-cell lung cancer
    R. Blanco, I. Maestu, M.G. de la Torre, A. Cassinello, I. Nuñez
    Annals of Oncology.2015; 26(3): 451.     CrossRef
  • Age dependent prognosis in concurrent chemo-radiation of locally advanced NSCLC
    Olfred Hansen, Tine Schytte, Morten Nielsen, Carsten Brink
    Acta Oncologica.2015; 54(3): 333.     CrossRef
  • How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non–Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial
    Hans H. Strøm, Roy M. Bremnes, Stein H. Sundstrøm, Nina Helbekkmo, Ulf Aasebø
    Clinical Lung Cancer.2015; 16(3): 183.     CrossRef
  • Therapie des Analkarzinoms
    I. Fraunholz, G. Woeste, R.-D. Hofheinz
    Der Onkologe.2014; 20(2): 173.     CrossRef
  • Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010
    Ellen J. F. van Reij, Max Dahele, Peter M. van de Ven, Patricia F. de Haan, Wilko F. A. R. Verbakel, Egbert F. Smit, Ben J. Slotman, Suresh Senan
    Acta Oncologica.2014; 53(3): 316.     CrossRef
  • The Efficacy of External Beam Radiotherapy for Airway Obstruction in Lung Cancer Patients
    Jeong Won Lee, Jong Hoon Lee, Hoon-Kyo Kim, Byoung Yong Shim, Ho Jung An, Sung Hwan Kim
    Cancer Research and Treatment.2014; 47(2): 189.     CrossRef
  • Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer
    Mun Sem Liew, Joseph Sia, Maud H. W. Starmans, Ali Tafreshi, Sam Harris, Malcolm Feigen, Shane White, Allan Zimet, Philippe Lambin, Paul C. Boutros, Paul Mitchell, Thomas John
    Cancer Medicine.2013; 2(6): 916.     CrossRef
  • Strahlentherapie im Alter
    A.-L. Grosu, K. Henne
    Forum.2013; 28(3): 170.     CrossRef
  • 12,940 View
  • 84 Download
  • 15 Crossref
Close layer
Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity in Locally Advanced Cervical Carcinoma
Tae Sung Lee, Mi Suk Kim, Suk Bong Koh, Youn Seok Choi
Cancer Res Treat. 2002;34(3):186-190.   Published online June 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.3.186
AbstractAbstract PDF
PURPOSE
The purpose of this study was to test the hypothesis that neoadjuvant chemotherapy (NACT) does not increase morbidity in patients undergoing radical hysterectomy with lymphadenectomy for locally advanced cervical cancer. MATERIALS AND METGODS: A retrospective study was undertaken of 140 patients with locally advanced cervical cancer (FIGO stage Ia to IIb) who underwent radical hysterectomy with lymphadenectomy by the same surgeon at the same hospital. Among the 140 patients, 39 received NACT followed by radical hysterectomy with pelvic lymphadenectomy (NACT group). This group received three cycles consisting of cisplatin 100 mg/m2/day on day 1 and 5-fluorouracil 1000 mg/m2/day from day 1 to 5. The NACT group was compared, in terms of intraoperative morbidity and postoperative morbidity, with the other 101 patients who underwent radical hysterectomy with lymphadenectomy but without chemotherapy (surgery-only group).
RESULTS
There were no significant differences in mean age, body weight or height between the two groups. The only significant difference was that the NACT patients had higher stages of cancer. The incidence of intraoperative morbidity did not differ between the NACT and surgery only patients. We considered the operation duration, amount of blood loss and need for transfusion as indicators of intraoperative morbidity. We could not find any significant differences in the duration of suprapubic catheterization, days of hemovac drainage, amount of drained hemovac fluid, days of hospitalization or postoperative febrile morbidity between the NACT and surgery-only groups. Patients in the surgery-only group had more postoperative complications (ureteral obstruction, intestinal obstruction, lymphocyst, lymphedema, and death) than the NACT group, although not to a statistically significant degree (P>0.05).
CONCLUSION
In this retrospective review, there was no evidence that NACT increased intraoperative or postoperative morbidity in patients with locally advanced cervical cancer. As this was a retrospective study, other prospective, randomized studies are needed to confirm these results.

Citations

Citations to this article as recorded by  
  • The Role of 2D/3D Ultrasound to Assess the Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
    Giorgia Perniola, Federica Tomao, Marialida Graziano, Innocenza Palaia, Margherita Fischetti, Francesca Lecce, Assunta Casorelli, Violante Di Donato, Antonella Giancotti, Francesco Antonio Battaglia, Ludovico Muzii, Pierluigi Benedetti Panici
    Oncology.2020; 98(11): 807.     CrossRef
  • 4,423 View
  • 20 Download
  • 1 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP